Menopause liver disease: what the research shows

What happens to the liver when estrogen declines after menopause?

When estrogen declines after menopause, the liver becomes more vulnerable to fat accumulation, inflammation, and scarring — a progression that researchers studying menopause, liver disease, and metabolic risk now describe as a distinct biological pathway, not simply a consequence of aging or weight.

Estrogen regulates how liver cells process fat, suppresses inflammatory signals, and influences insulin sensitivity. When ovarian estrogen production drops sharply at menopause, all three functions shift at once, and the liver must adapt to a different hormonal environment — sometimes without managing that adaptation well.

A 2025 review published in a gastroenterology journal examined this pathway in detail. That review describes how estrogen loss after menopause changes fat metabolism in the liver, promotes low-grade inflammation, and accelerates the progression of MASH — metabolic dysfunction-associated steatohepatitis, a form of fatty liver disease involving both fat buildup and liver cell injury. Women in this study showed higher rates of MASH progression after menopause compared with premenopausal women, even after accounting for other metabolic factors.

Three specific mechanisms matter:

Estrogen normally suppresses inflammatory proteins in liver tissue. When estrogen falls, those proteins become more active, and chronic low-level inflammation damages liver cells over time.

Fat redistribution after menopause — particularly the shift toward more fat stored around the abdomen and organs — increases the amount of fatty acids the liver receives and must process.

Insulin resistance, which tends to worsen after menopause, makes the liver work harder to manage blood sugar, and that extra metabolic load compounds the fat accumulation already underway.

The same review notes that this progression can move from simple fat accumulation (steatosis) to fibrosis — scarring of liver tissue — and that the postmenopausal hormonal environment appears to speed that transition. The trial did not establish that every postmenopausal woman will develop liver disease; individual risk depends on genetics, body composition, diet, alcohol use, and other health conditions.

An expert position statement from the Spanish Menopause Society flags liver health as part of the broader metabolic picture in peri- and postmenopausal women with obesity, noting that incretin-based therapies — a class of medicines that includes GLP-1 receptor agonists — are being studied in this population partly because of their effects on liver fat. That statement does not establish those medicines as standard care for liver disease in this group, and women in that discussion were specifically those with obesity, not all postmenopausal women.

Evidence gaps remain real. Most mechanistic research has been done in animal models or in studies that did not separate the effects of estrogen loss from the effects of aging, weight change, or other hormonal shifts that happen around the same time. Human trial data specific to liver outcomes in postmenopausal women is still accumulating.

This section is for general health education only and is not medical advice. Speak with a qualified clinician about your individual health history, liver function, and any treatment decisions.

How does menopause liver disease progress to fibrosis?

Menopause liver disease progresses to fibrosis through a chain of events that estrogen loss sets in motion: falling estrogen levels disrupt fat metabolism in the liver, drive inflammation, and push liver cells toward scarring over time. The evidence for this sequence comes primarily from research on metabolic dysfunction-associated steatohepatitis (MASH)—a condition where fat builds up in the liver, triggers inflammation, and, if unchecked, causes the liver to replace healthy tissue with stiff scar tissue called fibrosis.

One 2025 review mapped the menopause-obesity axis in MASH progression and described the biological steps in detail. Estrogen normally keeps fat from accumulating in the liver by regulating how liver cells take up, store, and burn fatty acids. When estrogen declines at menopause, that regulation weakens. Fat builds up inside liver cells—a stage called steatosis. Steatosis alone does not cause fibrosis, but it makes liver cells fragile and reactive.

Fat-laden liver cells then release chemical signals that recruit immune cells. Those immune cells release inflammatory molecules, including tumor necrosis factor-alpha (TNF-α), which damages liver tissue directly. The same review identified estrogen decline as a driver of this inflammatory shift, and noted that visceral fat—the fat stored around abdominal organs, which increases after menopause—amplifies the signal further.

Chronic inflammation activates a specific liver cell type called a hepatic stellate cell. Stellate cells are normally dormant. Inflammation wakes them and turns them into collagen-producing machines. Collagen is the protein that forms scar tissue. Repeated cycles of injury and collagen deposition gradually stiffen the liver. That stiffening is fibrosis.

The evidence makes several points clear:

• Women in this study who had both estrogen deficiency and obesity showed faster MASH progression than those with either factor alone, suggesting the two interact rather than simply add together.
• The review did not establish that menopause causes fibrosis in every postmenopausal woman—individual metabolic health, genetics, alcohol use, and other factors all shape the trajectory.
• Fibrosis is graded on a scale (F0 to F4); early-stage fibrosis (F1–F2) can stabilize or improve with metabolic changes, while advanced fibrosis (F3–F4, also called cirrhosis) is harder to reverse.

Most studies in this area have been conducted in postmenopausal women with obesity, so the findings may not apply equally to women at different life stages, body compositions, or with different metabolic profiles.

This section is for general health education only and does not constitute medical advice. Speak with a qualified clinician about your individual health situation.

What did the 2025 incretin therapy position statement find in perimenopausal and postmenopausal women?

The 2025 incretin therapy position statement from the Spanish Menopause Society found that women in perimenopause and postmenopause face a distinct metabolic picture — one where menopause, liver disease risk, and body-fat redistribution interact in ways that make incretin-based medicines worth examining specifically for this life stage, not just as a general obesity treatment.

The position statement addresses GLP-1 receptor agonists and dual GIP/GLP-1 agonists (incretin-based therapies — medicines that mimic gut hormones to regulate blood sugar and appetite) in the context of menopause-related metabolic change. Estrogen decline after menopause shifts fat storage toward the abdomen and liver, raising the risk of metabolic dysfunction-associated steatohepatitis (MASH) — a condition where fat builds up in liver cells and can progress to scarring. The menopause-obesity axis describes this pathway in detail, and the position statement draws on that biology to frame its recommendations.

Key findings:

• Women in this study population — perimenopausal and postmenopausal women with obesity — showed metabolic profiles that differ from premenopausal women and from men, including greater visceral fat accumulation and altered insulin sensitivity tied to estrogen loss.
• The position statement reports that incretin therapies reduced body weight and improved cardiometabolic markers in trial populations that included postmenopausal women, but the trials were not designed to isolate menopause status as a variable, so the statement cannot confirm that effects stem from menopause status alone.
• The statement does not establish that any incretin medicine is safe or effective specifically for perimenopausal women as a defined group — the trial data lack the granularity to support that claim.
• Bone health emerges as a gap. Rapid weight reduction can reduce bone mineral density, and postmenopausal women already carry elevated fracture risk. The statement calls for more data on skeletal outcomes in this population.
• Cardiovascular benefit data from large trials included postmenopausal women, but the statement notes those trials were not powered to report menopause-specific subgroup results.

The evidence here is real but incomplete. The position statement is expert consensus built on existing trial data, not a new clinical trial. It reflects the best current interpretation of available evidence — and the gaps it names are genuine, not caution for its own sake.

This content is for general health information only and is not medical advice. Speak with a qualified clinician before making any decisions about medicines, treatments, or health management.

What did the SGLT2 inhibitor study find in postmenopausal women with type 2 diabetes?

The SGLT2 inhibitor study found that women in this study who took SGLT2 inhibitors had significantly lower blood levels of a protein called Sema3A compared with women in this study who did not take these drugs. That matters because Sema3A is linked to bone loss and inflammation — two concerns that rise sharply after menopause, a life stage already tied to liver disease risk and metabolic change.

What the study measured

Women in this study were postmenopausal and had type 2 diabetes. The researchers used propensity score matching, which pairs participants with similar background characteristics so the drug effect is easier to isolate.

SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) are a class of diabetes medicines that lower blood sugar by making the kidneys release extra glucose in urine. They are not peptide medicines, but their effects on signaling proteins matter to how researchers think about bone and metabolic health in this population.

Women in this study who took SGLT2 inhibitors showed suppression of the Sema3A/NRP1/Plexin-A1 signaling axis. This axis works as a communication chain: Sema3A sends a signal, NRP1 and Plexin-A1 receive it, and the chain influences bone cell activity and inflammation.

The trial did not establish whether suppressing this axis improves bone density, reduces fracture risk, or produces any specific clinical outcome for postmenopausal women. The study measured the signal, not the downstream result.

The evidence gap

Observational and matched analyses like this one can show an association between a drug and a biological signal. They cannot prove the drug caused a health benefit or harm through that signal. Researchers would need longer, controlled trials to answer that question.

Women in this study were a specific group — postmenopausal, with type 2 diabetes, and already candidates for SGLT2 inhibitor therapy under standard care. The findings do not apply to premenopausal women, women without diabetes, or women at different life stages. Biology varies across all of these groups, and the signaling pathways involved respond differently depending on estrogen status and metabolic context.

If you or someone you care for takes an SGLT2 inhibitor and wants to understand what this research means for their situation, a prescribing clinician is the right person to ask.

This section is for general health education only and is not medical advice. It does not replace a conversation with a qualified healthcare provider about your individual circumstances.

What are the biggest evidence gaps in menopause liver disease research?

The biggest evidence gaps in menopause liver disease research are real and consequential: the studies that exist are mostly short, small, and built around populations that don't reflect the full range of women's biology, life stage, or metabolic history.

The Spanish Menopause Society position statement on incretin-based therapies in peri- and postmenopausal women with obesity names this directly. Women in this statement's review were largely absent from the foundational cardiovascular and metabolic trials that shaped current prescribing. Clinicians are often extrapolating from data collected in men or in mixed-sex populations where results were not broken down by menopausal status.

The gaps cluster in a few specific areas:

Perimenopause as a distinct stage. Most liver disease research groups women as either "premenopausal" or "postmenopausal." The transition itself — when estrogen levels fluctuate rather than simply decline — gets almost no dedicated study. The MASH progression review (MASH stands for metabolic dysfunction-associated steatohepatitis, a form of liver inflammation tied to fat accumulation) describes the estrogen-decline-to-liver-fibrosis pathway in postmenopausal terms, leaving the perimenopause window largely uncharacterized.

Mechanistic data in humans. The MASH review maps how falling estrogen affects liver fat and scarring, but much of the underlying mechanism work comes from animal models. Human trial data confirming those pathways — especially across different racial and ethnic groups — remains sparse.

Long-term outcomes. Women in this study's incretin trials were followed for months, not decades. Liver fibrosis develops over years. The Spanish Menopause Society statement acknowledges that long-term safety and efficacy data for GLP-1-based therapies in this population simply do not exist yet.

Interaction with hormone therapy. Whether menopausal hormone therapy modifies liver disease risk or changes how peptide medicines work in the liver is not settled. The MASH review raises the question without resolving it.

Diversity in study populations. Age at menopause, body composition, and metabolic risk vary across ethnic groups. The available studies do not capture that variation in a way that lets researchers — or clinicians — draw conclusions for women outside the studied groups.

These gaps don't mean the research is useless. They mean the findings apply most confidently to women who resemble the people actually studied, and that anyone making clinical decisions should weigh that context carefully.

This section is for general health education only and is not medical advice. Speak with a qualified clinician about your individual health situation.